SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened market interest as investors monitor upcoming Binance burn events and speculate on potential supply shocks driven by on-chain activity. The community remains deeply divided, with optimistic holders aggressively buying dips in anticipation of a recovery, while critics caution against the project's historical volatility.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

Spermwhale is experiencing intense social media activity as traders debate its potential for massive gains versus risks of a rapid decline, with community sentiment split between fervent 'whale' supporters and critics labeling it a speculative meme project. Investors are actively discussing the coin's momentum and comparing it to other emerging tokens, driving speculative volume as many hope to catch an upward surge.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DRB is gaining traction as community members circulate the narrative that the Grok AI wallet has generated significant fees from the token, fueling speculation about its potential for a broader breakout. Investors are actively discussing its role within the Base ecosystem and the possibility of future exchange endorsements, highlighting a high-conviction sentiment among early adopters.

Alchemy Pay

Alchemy Pay is drawing significant attention from the community as investors debate the potential of its upcoming Layer 1 blockchain and ongoing U.S. regulatory expansion through new money transmitter licenses. While bulls point to these infrastructure developments as a catalyst for future utility and adoption, the community remains polarized with vocal debates between long-term supporters and critics who question the project's tokenomics and long-term price performance.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as the community highlights its prominent role in the real-world asset (RWA) sector, driven by institutional partnerships with major players like BlackRock and Franklin Templeton. While many investors remain focused on the long-term potential of institutional on-chain finance, discussions are also tempered by concerns regarding token supply unlocks and price volatility.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWX Technologies is capturing investor interest as a vital play on the nuclear renaissance, driven by robust defense contracts and its role as a key manufacturing partner for Small Modular Reactor (SMR) development. The community is actively discussing the company's dual positioning in national security and the growing power demands of AI data centers, often highlighting its established profitability compared to speculative sector peers.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor ($TAO) is seeing significant bullish momentum as the community increasingly positions it as the premier infrastructure play for decentralized artificial intelligence. Investors are highlighting its scarcity mechanics and ecosystem growth as key drivers, with many actively comparing its long-term potential to the early adoption phases of Bitcoin.

GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF

GraniteShares 2x Long NVDA Daily ETF

NVDL is trending as investors aggressively buy the dip following recent market volatility, with the community actively debating whether to hold leveraged positions through earnings or trade the intraday price swings. Discussions center on technical support levels and the broader impact of tech sector headlines, with many traders using NVDL to capitalize on Nvidia's volatility while managing concerns over decay.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is currently trending as investors speculate on a potential GameStop acquisition and digest ongoing rumors about the company's future strategic direction. The community remains divided, with intense debate centered on the feasibility of the merger, the impact of potential retail-driven buying, and skepticism regarding the company's valuation and business model.

Netskope, Inc. engages in the provision of cloud based security solutions. It offers business developing analytics for visibility, policy enforcement and other cloud solutions. Its products include Netskope one SASE, Netskope one SSE, cloud access security broker, next generation secure web gateway, private access, cloud firewall, SD-WAN and skopeAI. The company was founded by Sanjay Beri, Lebin Cheng, Ravishankar Ithal, and Krishna Narayanaswamy in October 2012 and is headquartered in Santa Clara, CA.

Netskope Inc. - Ordinary Shares - Class A

Netskope is generating significant buzz following an expanded partnership with Google Cloud to integrate AI security guardrails, while the community actively debates whether the stock's recent volatility presents a long-term acquisition opportunity or a sign of deeper operational struggles. Investors are closely tracking institutional accumulation alongside concerns regarding upcoming lock-up expirations and the broader competitive landscape for cybersecurity-focused AI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

VolitionRx Announces Acceptance of Compliance Plan by NYSE American VolitionRx Announces Acceptance of Compliance Plan by NYSE American PR Newswire HENDERSON, Nev., April 23, 2026 HENDERSON, Nev...

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update PR Newswire...

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in...

Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients

Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma...

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update PR...

VolitionRx Reports Over 95% Early Cancer Detection in Breakthrough Liquid Biopsy Study

VolitionRx Limited (NYSE:VNRX) unveiled promising new data that could reshape the landscape of early cancer detection, reporting over 95% sensitivity in identifying stage I and II cancers using its proprietary Capture-Seq liquid biopsy technology.

<ul class="summary-bullets"><li>Volition stated in its announcement that the detection rate for stage I cancer was 94%, with its Capture-Seq method detecting in 17 of 18 samples.</li><li>Its detection rate for stage II cancer stood at 96%, stage III cancer at 100%, and stage IV cancer at 91%.</li><li>Volition stated that its Capture-Seq method overcomes the hurdles in the liquid biopsy space, where the vast majority of circulating DNA in blood plasma samples comes from healthy cells rather than cancer cells.</li></ul>VolitionRx (VNRX) shares ripped more than 34% in Wednesday’s pre-market trade&nbsp;before paring gains to hover 16% higher in the opening trade after the company announced proof-of-concept data from a blinded validation cohort for the detection of cancer.The company said that it has developed a new liquid biopsy method, and during a blind validation cohort, it achieved over 95% sensitivity for stage I &amp; II cancers with 95% specificity.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VNRX">Volition</a> trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Detection Rates Across Cancer Stages</h2>Volition stated in its announcement that the detection rate for stage I cancer was 94%, with its Capture-Seq method detecting in 17 of 18 samples. Its detection rate for stage II cancer stood at 96%, stage III cancer at 100%, and stage IV cancer at 91%."We are now releasing the data from a blinded validation cohort of 81 subjects and are extremely encouraged by the results, particularly in early-stage cancer detection,” said Volition’s Chief Scientific Officer, Jake Micallef.The company’s Chief Commercial Officer, Gael Forterre, said that this technology represents a Total Addressable Market of nearly $23 billion for human Multi-Cancer Early Detection (MCED) tests, and $13 billion for Minimal Residual Disease (MRD) tests on an annualized basis.“We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development and launch of this technology as soon as possible,” Forterre added.<h2 class="st-heading-2">What Is Capture-Seq?</h2>Volition stated that its Capture-Seq method overcomes the hurdles in the liquid biopsy space, where the vast majority of circulating DNA in blood plasma samples comes from healthy cells rather than cancer cells. This makes it hard to detect the disease.The company says its method solves this problem, producing more than 99% pure cancer-derived plasma DNA sequence sets for liquid biopsy. This filters out the noise and improves detection accuracy.<a href="https://stocktwits.com/symbol/VNRX">VNRX stock</a> is down 23% year-to-date and 63% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 15% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-tanks-anavex-withdraws-alzheimers-drug-blarcamesine-eu/cZ3YF8WRISf">AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

VNRX Stock Soars 34% Pre-Market — What's Driving The Rally?

The company said it has developed a new liquid biopsy method, and in a blinded validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.

Equity

Volition Announces Detection of Over 95% of Early-Stage Cancers

Volition Announces Detection of Over 95% of Early-Stage Cancers Volition Announces Detection of Over 95% of Early-Stage Cancers PR Newswire HENDERSON, Nev., March 25, 2026 Blinded validation cohort...

<ul class="summary-bullets"><li>The company submitted an updated manuscript detailing a new two-step method to remove nearly all non-cancer DNA.</li><li>Early results showed no false positives and all cancers detected in the first group, along with strong validation in a second blinded cohort.</li><li>VolitionRx published a research paper in December 2025, that highlighted its Capture-Seq method for cancer detection.</li></ul>Shares of VolitionRx (VNRX) gave up a part of its pre-market gains to trade 30% higher on Wednesday after the diagnostics company unveiled what it called a potential breakthrough in cancer detection. The company said it was successful in isolating more than 99% pure circulating tumor-derived DNA (ctDNA) from blood samples of cancer patients.<a href="https://stocktwits.com/symbol/VNRX">VNRX stock</a> breached its 100-day moving average (100-DMA) for the first time since Oct. 8, 2025.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=AMEX%3AVNRX"><img src="https://news.stocktwits-cdn.com/VNRX_jpg_e886d96646.webp" alt="VNRX.jpg"></a>Source: TradingViewThe company submitted an updated manuscript detailing a new two-step method that combines physical sample enrichment with advanced bioinformatics to remove nearly all non-cancer DNA. This addresses a key challenge in liquid biopsy, where most circulating DNA typically comes from healthy cells.“Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA,” said Jake Micallef, Chief Scientific Officer of Volition.“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years,” Micallef added.The early results are encouraging, with no false positives and all cancers detected in the first group, along with strong validation in a second blinded cohort, VolitionRx said. The company is now working on further testing in early-stage cancers.<h2 class="st-heading-2">VolitionRx’s Capture-Seq Method for Cancer Detection</h2>VolitionRx published a research paper in December 2025, that highlighted its Capture-Seq method and novel biomarkers for cancer detection. The technology enables accurate and potentially low-cost testing across multiple cancers.&nbsp;It works by enriching ultrashort DNA fragments in blood, achieving a 180-fold increase in detection sensitivity. This approach focuses on DNA within chromosome fragments, unlike traditional methods that analyze extracted DNA.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits completely flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.Despite shedding gains, retail chatter remained primarily bullish, with one user asking for patience.<stembedurl>https://stocktwits.com/SuellenD/message/647851536</stembedurl>Another user said buy the dip.<stembedurl>https://stocktwits.com/SuellenD/message/647840635</stembedurl>Year-to-date, the stock has shed around 8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Why Is VNRX Stock Soaring Over 30% Today?

The company said it can isolate pure tumor DNA from blood, which potentially solves a key bottleneck in liquid biopsy.

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating...

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

VNRX
VolitionRX Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VNRX News

VNRXVolitionRX Ltd